Acarix' share issue well oversubscribed in connection with the initial public offering on Nasdaq First North Premier in Stockholm - Seite 2

Vator Securities acted as global co-ordinator and sole bookrunner in the initial public offering.

After the new share issue has been registered at Bolagsverket (the Swedish Companies Registration Office), the total number of shares in Acarix will increase by 7,960,000 to 23,027,376 representing an increase of the share capital and votes of 53 per cent.

Advisors

Vator Securities is the financial advisor and Baker & McKenzie is the legal advisor to the Company in connection with the new share issue and initial public offering on Nasdaq First North Premier. Wildeco is the Certified Advisor to the Company.

For more information, please contact:

Søren Rysholt Christiansen, CEO, Acarix
E-mail: [e-mail]
Phone: [phone]

Notes to editors:
Acarix , CADScor®System and cardiac sound measurement

Acarix was established in 2009 as a spinout company from Coloplast A/S. Since 2010 key investors Seed Capital (DK) and Sunstone Life Science Ventures (DK) have financed the development of the company and supported it towards market introduction. While some founders remain in the company, Acarix has attracted a highly experienced management team who have held senior positions in international medical device companies - CEO Søren Rysholt Christiansen with ELOS Medtech, GN ReSound and Cook Medical.

Acarix' CADScor^®System is based on pioneering research at Aalborg University. It has long been known that both cardiac contraction movement and turbulent flow can generate sound. Contraction related sounds are in lower frequency, whereas turbulent sounds in the streaming blood caused by partial obstruction (stenosis) in the coronary arteries are of higher frequencies. The detection of these murmurs is delicate, since the energy of the murmurs is very weak. Detecting and recording the coronary murmurs requires not only an advanced sensor but also means for proper attachment to the skin above the heart to optimize the recorded signal and to avoid external noise.

The Acarix CADScor^®System has been designed to be an all-in-one system in the sense that the heart signal will be recorded, processed and displayed as a patient specific score, the CAD-score, on the device screen.

The CADScor^®System contains the necessary electronics to instruct professionals during use and guide the patient through the recording periods. The system also contains a docking station for daily qualification of the sensor. Further the system integrates with an adhesive patch for locking the CADScor^® sensor to a fixed position above the heart during the recording.